Cefepime Hydrochloride

Cefepime Hydrochloride, a broad-spectrum antibiotic, is being studied in several clinical trials to evaluate its effectiveness and safety in treating various conditions. These trials are investigating different administration methods, dosages, and combinations with other drugs to optimize treatment outcomes for patients with infections, neutropenia, and other medical conditions.

Table of Contents

What is Cefepime Hydrochloride?

Cefepime hydrochloride, also known by its brand name Maxipime, is a powerful antibiotic medication belonging to the fourth-generation cephalosporin class[1]. It is used to treat a variety of bacterial infections and is particularly effective against both gram-positive and gram-negative bacteria. Cefepime works by interfering with the bacteria’s cell wall synthesis, ultimately leading to their destruction[2].

What Conditions Does Cefepime Treat?

Cefepime is used to treat a wide range of infections, including:

  • Sepsis and Septic Shock: A life-threatening condition caused by the body’s response to infection[2]
  • Febrile Neutropenia: A condition where patients with low white blood cell counts develop fever, often seen in cancer patients undergoing chemotherapy[1]
  • Complicated Urinary Tract Infections (cUTI): Including acute pyelonephritis, which is a severe kidney infection[3]
  • Pneumonia: Particularly in nursing home residents[4]
  • Bacteremia: The presence of bacteria in the bloodstream[5]

Cefepime is often used in critically ill patients and those with compromised immune systems, such as cancer patients[6].

How is Cefepime Administered?

Cefepime is typically administered intravenously (through a vein) in a hospital or healthcare setting. The dosage and duration of treatment depend on the type and severity of the infection, as well as the patient’s kidney function. Some common administration methods include:

  • Intermittent Infusion: Given over 30 minutes every 8 hours[5]
  • Extended Infusion: Given over 3 hours every 8 hours[2]
  • Continuous Infusion: Given continuously over 24 hours[5]
  • Intramuscular Injection: In some cases, it can be given as a shot into a muscle[4]

The method of administration may affect the drug’s effectiveness and is often chosen based on the specific infection and patient characteristics.

Effectiveness of Cefepime

Cefepime has shown effectiveness in treating various infections. Some key points about its efficacy include:

  • It is often compared to other antibiotics like ceftriaxone in treating nursing home-acquired pneumonia[4]
  • In febrile neutropenia, it has been compared to levofloxacin for reducing fever and controlling infection symptoms[6]
  • Research is ongoing to determine if continuous infusion of cefepime is more effective than intermittent dosing in critically ill patients[5]

The effectiveness of cefepime can be measured by clinical cure rates, microbiological eradication (elimination of bacteria), and time to fever resolution.

Cefepime in Special Populations

Cefepime’s use and dosing may need to be adjusted in certain patient groups:

  • Patients with Kidney Problems: The dosage of cefepime may need to be adjusted in patients with varying degrees of renal (kidney) impairment[7]
  • Cancer Patients: Cefepime is often used in cancer patients with febrile neutropenia, but special considerations may be needed due to their compromised immune systems[1]
  • Elderly Patients: Older adults, particularly those in nursing homes, may receive cefepime for conditions like pneumonia, but dosing may need to be adjusted[4]

Safety and Side Effects

While cefepime is generally considered safe, like all medications, it can cause side effects. Common side effects may include:

  • Headache
  • Nausea
  • Diarrhea
  • Rash

More serious side effects, though rare, can include severe allergic reactions and seizures. Ongoing research continues to evaluate the safety profile of cefepime in various patient populations[7].

Ongoing Research and Future Directions

Research on cefepime is ongoing, with several areas of focus:

  • Combination Therapies: Studies are investigating the use of cefepime in combination with other drugs, such as AAI101, to potentially enhance its effectiveness against resistant bacteria[3]
  • Optimizing Administration: Research is exploring different infusion methods to maximize the drug’s effectiveness[5]
  • Intrapulmonary Pharmacokinetics: Studies are examining how cefepime behaves in lung tissue, which could be important for treating respiratory infections[8]

These ongoing studies aim to improve the use of cefepime and potentially expand its applications in treating various infections.

Aspect Details
Administration Methods Intravenous infusions (30 minutes, 3 hours, continuous), Intramuscular injections
Conditions Studied Febrile neutropenia, Complicated urinary tract infections, Sepsis, Bacteremia, Pneumonia
Combinations Tested Cefepime + AAI101, Cefepime + Zidebactam, Cefepime + Metronidazole
Primary Outcomes Clinical cure rates, Microbiological cure rates, Time to fever resolution, Mortality rates
Secondary Outcomes Pharmacokinetics, Safety profiles, Cost-effectiveness
Patient Populations Cancer patients, Critically ill patients, Nursing home residents, Patients with renal impairment

Ongoing Clinical Trials on Cefepime Hydrochloride

  • Study on Reducing Antibiotic Use in Severe COPD Exacerbation with Amoxicillin, Cefotaxime, and Ciprofloxacin for Patients on Mechanical Ventilation or Oxygen Therapy

    Recruiting

    1 1 1 1
    Investigated diseases:
    France
  • Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

    Not yet recruiting

    1 1 1 1
    France
  • Study Comparing Different Antibiotic Treatments for ICU Patients with Hospital-Acquired Sepsis: Focus on Cefepime and Drug Combination

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    France
  • Study on Nebulized Amikacin for Treating Ventilator-Associated Gram-Negative Pneumonia in Patients on Veno-Arterial ECMO

    Not yet recruiting

    1 1 1
    France

Glossary

  • Febrile Neutropenia: A condition characterized by fever and an abnormally low number of neutrophils (a type of white blood cell) in the blood, often occurring as a side effect of cancer treatments.
  • Complicated Urinary Tract Infection (cUTI): A urinary tract infection that has additional factors making it more difficult to treat, such as structural abnormalities or catheterization.
  • Bacteremia: The presence of bacteria in the bloodstream, which can lead to serious infections throughout the body.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Microbiological Cure: The elimination of the bacteria causing an infection, as confirmed by laboratory tests.
  • Intravenous (IV) Infusion: A method of administering medication directly into a vein over a period of time.
  • Defervescence: The reduction or disappearance of fever.

References

  1. https://clinicaltrials.gov/study/NCT01484015
  2. https://clinicaltrials.gov/study/NCT02820987
  3. https://clinicaltrials.gov/study/NCT03680612
  4. https://clinicaltrials.gov/study/NCT00358202
  5. https://clinicaltrials.gov/study/NCT00609375
  6. https://clinicaltrials.gov/study/NCT00020865
  7. https://clinicaltrials.gov/study/NCT03680352
  8. https://clinicaltrials.gov/study/NCT04951505